Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

and expectations. These forward-looking statements include statements regarding the timing of enrollment and rate of MACE in the Light Study, the ability to gain agreement with FDA on the procedural details for a Contrave NDA resubmission in advance of the Light Study interim data, the timing of the subsequent resubmission of the NDA for Contrave, the timing of approval for Contrave, the submission of an application for marketing authorization in Europe and the negotiation of a partnership for the rest-of-world rights to Contrave and Empatic, the expected cash balance at the end of 2012, the expected cash usage for the year 2012, the development of Empatic and the communication with the FDA, the possibility that a cardiovascular outcomes trial will be needed for Empatic, and the commercial potential of Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct the Light Study and the progress and timing thereof; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study or Phase III trials for Empatic; the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; the potential for the FDA to not approve Contrave or Empatic; the potential for early termination of the collaboration agreement betwe
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... strategic transaction processSAN DIEGO, May 7 ADVENTRX ... today announced results from its bioequivalence study of ... have comparable overall safety as Taxotere(R), the reference ... severe toxicities. However, pharmacokinetic equivalence, the primary ...
... is to Enhance Patient Safety and Reduce Health Care ... will join in a pilot program, contributing data on ... the data collected, it will be possible to identify ... patient safety while reducing overall costs to the health ...
Cached Medicine Technology:ADVENTRX Announces Results From ANX-514 Bioequivalence Study 2ADVENTRX Announces Results From ANX-514 Bioequivalence Study 3ADVENTRX Announces Results From ANX-514 Bioequivalence Study 4ADVENTRX Announces Results From ANX-514 Bioequivalence Study 5National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3
(Date:7/13/2014)... best treatment and variations in the quality of care ... cancer patients still varies widely between regions within Europe, ... European adults to date, published in The Lancet ... survival for most cancers of the blood has increased ... approval of new targeted drugs in the early 2000s ...
(Date:7/13/2014)... Intraocular Lens (IOL) Market: Global Industry ... 2019 , Intraocular lens (IOL) is inserted in the ... The lenses are inserted inside the eye, after removal ... replaces the focusing power of natural lens. The pseudophakic ... deliver the light focusing function which was originally undertaken ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
(Date:7/13/2014)... The North American water storage systems market is estimated to ... 2018, at a CAGR of 21.0%, from 2013 to 2018. ... pace in North America. The U.S. is experiencing high growth ... storage and collection, and the increased spending on modernization and ... healthy rate in Canada, and is rising at a rapid ...
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3
... 11 (HealthDay News) -- Parkinson,s disease patients who receive care ... break a hip or need nursing-home placement than those treated ... American researchers looked at the medical records of all ... Between that time and 2005, 68 percent of the patients ...
... drugs as a first-line treatment for people with tuberculosis (TB) ... not been well understood. Now, researchers have discovered a key ... TB therapy. The finding potentially paves the way for the ... an infected individual even more rapidly. The study was supported ...
... THURSDAY, Aug. 11 (HealthDay News) -- What do a ... A lot more than you might expect, new research ... aquatic reptile with its embryo offers the first evidence ... that they may have had a social structure similar ...
... August 11, 2011) According to a study ... the American Society of Hematology (ASH), researchers have ... that releases stem cells from the bone marrow into the ... risk for later development of abnormalities involving loss or gains ...
... , THURSDAY, Aug. 11 (HealthDay News) -- American women ... those born in 1910 or 1960, according to researchers who analyzed ... 1935 had an average of three children per woman, compared with ... for those born in 1960, their study found. Of the ...
... 11 (HealthDay News) -- Like humans, chimpanzees are born ... to track the development of three chimpanzees, brains from ... areas of the brain that play an important role ... and creativity are immature in both chimps and humans, ...
Cached Medicine News:Health News:Parkinson's Patients May Fare Better in Neurologist's Care 2Health News:Prehistoric Water Reptile's Social Life Similar to Dolphins: Study 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Women Born After Great Depression Had More Children, Study Finds 2
... CELL-DYN 1800 is the latest 3-part differential ... since the founding of the CELL-DYN line. ... data management capabilities, the CELL-DYN 1800 meets ... CELL-DYN 1800 is smaller than its predecessors ...
... Net Point-of-Care Data Networking is hospital ... of data networking. In seconds, point ... be transferred from nursing stations throughout ... is instantly available to laboratory staff ...
... EarlyDetect® Menopause Test is a one ... menopause has occured. This test can ... follicle-stimulating hormone (FSH), which indicates whether ... simple to use and in a ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
Medicine Products: